Shield Therapeutics PLC 2021 Annual Report and 2022 AGM Notice (7075Q)
30 Junio 2022 - 1:01AM
UK Regulatory
TIDMSTX
RNS Number : 7075Q
Shield Therapeutics PLC
30 June 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
2021 Annual Report and 2022 AGM Notice
London, UK, 30 June 2022: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with an initial focus on
addressing iron deficiency, announces that the following documents
have now been sent to shareholders:
-- Annual Report and Accounts for the year ended 31 December 2021
-- Notice of Annual General Meeting ("AGM") 2022
In accordance with AIM Rule 26, these documents are also
available to view on the Company's website:
https://www.shieldtherapeutics.com/corporate-documents/
We are delighted to be able to welcome back our shareholders who
are able to join us at our AGM. This year the Company's AGM will be
held at 2pm (BST) on 27 July 2022 at the offices of Shield
Therapeutics plc, Northern Design Centre, Baltic Business Quarter,
Gateshead Quays, England NE8 3DF. Should restrictions be imposed
that prevent this Meeting from being held in person the Company has
made provisions for this Meeting to be held both virtually and
electronically and details will be provided to shareholders.
If you wish to attend the AGM in your capacity as a shareholder,
please bring proof of shareholding or if shares are held through a
nominee account, a letter of representation, to facilitate your
entry to the Meeting.
The Company will provide a facility for shareholders to join the
AGM online and telephonically and there will be an opportunity for
shareholders to ask questions. In order to facilitate the process,
the Board would request that shareholders register for the meeting
and submit questions in advance, before 2.00pm (BST) on 25 July
2022.
To register for dial-in details and to submit any questions
please contact Walbrook PR via email at shield@walbrookpr.com or
call +44 (0)20 7933 8787.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice
Lane/Nigel Birks +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Paul McManus/Lianne Applegarth/Alice +44 (0)20 7933 8780 or shield@walbrookpr.com
Woodings
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Accrufer (R) /Feraccru (R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
absorption compared to other oral iron therapies and has been shown
to be an efficacious and well-tolerated therapy in a range of
clinical trials. More information about Accrufer(R)/ Feraccru(R) ,
including the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched
Accrufer(R) in the US and Feraccru(R) is commercialized in the UK
and European Union by Norgine B.V., who also have the marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of Accrufer(R) /
Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE
Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMZGZVVLFGZZM
(END) Dow Jones Newswires
June 30, 2022 02:01 ET (06:01 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024